ProBCI
There is a pressing need for predictive biomarkers to personalize bladder cancer treatment. Patients with bladder cancer will be prospectively recruited for the Prospective Bladder Cancer Infrastructure (ProBCI) with longitudinal assessments from primary diagnosis until death. This infrastructure has the following objectives:
- Inform on the epidemiology of bladder cancer in the Netherlands and the treatment evolution landscape;
- Facilitate the selection of eligible patients for specific intervention studies, thereby improving accrual rates;
- Facilitate the identification of historical or concurrent control groups for future single arm intervention studies;
- Validate the efficacy and safety of novel diagnostic and therapeutic approaches in a real-world patient population;
- Evaluate the impact of bladder cancer treatment on patient reported outcomes;
- Provide access to blood and tumor tissue of bladder cancer patients for biomarker discovery and validation studies and organoid culture.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched
26 November 2021The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.
read more
New Automated PBMC isolation method introduced in LMI.
21 September 2021The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.
read more
Health-RI, geared up to accelerate
21 September 2021The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.
read more
SUNRISE-CRC sub-biobank
21 September 2021The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.
read more
PRECISE sub-biobank
21 September 2021The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.
read more
Lysine Metabolism sub-biobank
21 September 2021Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.
read more